Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimetoran DDI Study with Phenytoin and Midazolam
NCT05901714Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of afimetoran in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 53 days, Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration up to 53 days and 1 more. Started Jun 2023; status: completed.
02
Drugs
afimetoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT05901714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05901714.